Who owns enGene Therapeutics Inc., from the filings themselves: stakes over 5% (Schedule 13D/G), the institutional managers reporting the stock each quarter (13F), and the funds holding it (N-PORT).
Investors crossing 5% ownership must disclose it. Schedule 13G filers certify the stake is passive; Schedule 13D is the general form for everyone else — founders, strategic holders, and activists alike. Each entry is the holder's most recent disclosure. Coverage begins with SEC's structured filings from December 18, 2024; a holder appears once they file or amend after that date.
Venrock Healthcare Capital Partners III, L.P.: 0.0% · 0 shares — VHCP Co-Investment Holdings III, LLC: 0.0% · 0 shares — Venrock Healthcare Capital Partners EG, L.P.: 0.0% · 0 shares
Perceptive Advisors LLC: 10.0% · 6,899,803 shares — Joseph Edelman: 10.0% · 6,899,803 shares — Perceptive Life Sciences Master Fund, Ltd.: 10.0% · 6,899,803 shares
11 more 5% stakes behind a free account
See every investor who has disclosed crossing 5% of enGene Therapeutics Inc..
Sign up freeEvery institutional manager whose latest 13F reports this stock, largest position first. "% of their portfolio" is the weight inside that manager's own book — how much conviction the position represents; "% of company" is how much of enGene Therapeutics Inc. they hold. Together these 90 managers report 117.90% of shares outstanding.
| Investor | Position value | Shares | % of their portfolio | % of company | As of |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | $36.1M | 4,000,000 | 1.67% | 5.97% | December 31, 2025 |
| Venrock Adviser, LLC | $32.5M | 4,771,414 | 1.21% | 7.12% | March 31, 2026 |
88 more institutional holders behind a free account
See every manager reporting enGene Therapeutics Inc., how much of the company they hold, and how big the position is inside their own portfolio.
Sign up freeFunds disclosing this stock in their monthly N-PORT portfolio, with the position's share of the fund's net assets. Together these 13 funds hold 2.72% of shares outstanding — counted inside the manager totals above, not on top of them, since a fund's shares also appear in its manager's 13F.
| Fund | Position value | % of net assets | % of company | As of |
|---|---|---|---|---|
| Eventide Healthcare & Life Sciences Fund | $8.58M | 0.51% | 1.42% | December 31, 2025 |
| Franklin Biotechnology Discovery Fund | $3.54M | 0.34% | 0.73% | April 30, 2026 |
11 more funds behind a free account
See every fund holding enGene Therapeutics Inc. and what share of its net assets the position represents.
Sign up freeLoading...
